In Quiet Debut, Alzheimer's Drug Rollout Slowed By Questions, Skepticism

Redirecting to full article in 5 second(s)...

Persistent concerns about Aduhelm, the disease's first new treatment in about 20 years, are curbing access more than four months after regulators approved it.